Cargando…

Protective role of ceftriaxone plus sulbactam with VRP1034 on oxidative stress, hematological and enzymatic parameters in cadmium toxicity induced rat model

We investigated the protective role of ceftriaxone plus sulbactam with VRP1034 (Elores) on hematological, lipid peroxidation, antioxidant enzymatic activities and Cd levels in the blood and tissues of cadmium exposed rats. Twenty-four male rats were divided into three groups of eight rats each. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dwivedi, Vivek Kumar, Bhatanagar, Anuj, Chaudhary, Manu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Slovak Toxicology Society SETOX 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600523/ https://www.ncbi.nlm.nih.gov/pubmed/23554563 http://dx.doi.org/10.2478/v10102-012-0032-3

Ejemplares similares

P06 Pharmacokinetics and renal accumulation of VRP-034
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022)

CSE-1034 versus Ceftriaxone: Efficacy and Safety Analysis from a Randomized, Open-labeled Phase III Study in Complicated Urinary Tract Infections
por: Chaudhary, Manu, et al.
Publicado: (2018)

A Novel High Performance Liquid Chromatographic Method for Simultaneous Determination of Ceftriaxone and Sulbactam in Sulbactomax
por: Shrivastava, Sanjay Mohan, et al.
Publicado: (2009)

P07 Toxicokinetic profile of VRP-034
por: Murkunde, Yogeshkumar Vishnupant, et al.
Publicado: (2022)

Parameter Space Beyond “1034”
por: Zimmermann, F
Publicado: (2010)

Parameter Space Beyond 1034
por: Zimmermann, F
Publicado: (2010)

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections
por: Xin, Xiaojuan, et al.
Publicado: (2013)

Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
por: Roy, Dilip, et al.
Publicado: (2021)

An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam
por: Gondane, Ajitkumar A, et al.
Publicado: (2023)

Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study
por: Chaudhary, Manu, et al.
Publicado: (2017)

1373. Activity of Ceftriaxone–Sulbactam–EDTA Against Multi-Drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India
por: Girotra, Ruchi, et al.
Publicado: (2018)

1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline
por: Mir, Mohd Amin, et al.
Publicado: (2018)

1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis
por: Mandale, Pankaj, et al.
Publicado: (2018)

P05 In vivo efficacy of VRP-034 in lung and thigh infection models
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022)

1034. Automating Assessments of Vancomycin Appropriateness
por: Holmer, Haley K, et al.
Publicado: (2019)

In Vitro Susceptibility of Clinical Isolates to Ceftriaxone Alone and Ceftriaxone in Combination With Sulbactam or Tazobactam: A Comparative Study of Broad-Spectrum β-Lactam Antibiotics in India
por: Sanghavi, Sonali, et al.
Publicado: (2023)

Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial
por: Hamao, Nobuyoshi, et al.
Publicado: (2020)

Evaluation of ceftriaxone-sulbactam-disodium edetate adjuvant combination against multi-drug resistant Gram-negative organisms
por: Gupta, Shilpi, et al.
Publicado: (2020)

1984. Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients With Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis)
por: Mir, Mohd Amin, et al.
Publicado: (2018)

Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis
por: Kato, Hideo, et al.
Publicado: (2022)

Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial
por: Mir, Mohd Amin, et al.
Publicado: (2019)

VRP in urban areas to optimize costs while mitigating environmental impact
por: Cerrone, Carmine, et al.
Publicado: (2022)

Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates
por: Cusumano, Jaclyn A., et al.
Publicado: (2022)

P1034: HEALTHCARE UTILIZATION OF PATIENTS WITH HYPEREOSINOPHILIC SYNDROME IN EUROPE
por: Hwee, J., et al.
Publicado: (2022)

Ampicillin/sulbactam: Stevens-Johnson syndrome/toxic epidermal necrolysis
Publicado: (2021)

Comparison of Ceftizoxime Plus Ampicillin-Sulbactam versus Gentamicin Plus Ampicillin-Sulbactam in the Prevention of Post-Transplant Early Bacterial Infections in Liver Transplant Recipients: A Randomized Controlled Trial
por: Shafiekhani, Mojtaba, et al.
Publicado: (2020)

381. Effect of Ceftriaxone+sulbactam+disodium EDTA Combination in Treatment of Complicated Urinary Tract Infections Caused by Metallo Beta-lactamase Producing Enterobacterales: An Open Label Randomized Controlled Trial
por: Samantaray, Subhashree, et al.
Publicado: (2023)

CLIC CRAB CAVITY SPECIFICATIONS MILESTONE: M10.3.4
por: Ambattu, P, et al.
Publicado: (2010)

M10.3.4: CLIC crab cavity specifications completed
por: Dexter, A, et al.
Publicado: (2010)

PReS13-SPK-1034: looking for new monogenic forms of lupus
por: Crow, Y
Publicado: (2013)

1034. Risk Score for the Need of Mechanical Ventilation in Adults Presenting with Encephalitis.
por: Heck, Ashley N, et al.
Publicado: (2022)

A Comparative In Vitro Sensitivity Study of “Ceftriaxone–Sulbactam–EDTA” and Various Antibiotics against Gram-negative Bacterial Isolates from Intensive Care Unit
por: Singh, Sweta, et al.
Publicado: (2020)

Characterisation of the role of Vrp1 in cell fusion during the development of visceral muscle of Drosophila melanogaster
por: Eriksson, Therese, et al.
Publicado: (2010)

Ceftriaxone-induced hemolysis
por: Guleria, Vivek S., et al.
Publicado: (2013)

2197. Ceftriaxone Monotherapy vs. Ceftriaxone Plus Azithromycin for the Treatment of Community-Acquired Pneumonia in Hospitalized, Non-ICU Patients
por: Murter, Forrest, et al.
Publicado: (2019)

A 28-Days Sub-Acute Toxicity Study in Swiss Albino Mice to Evaluate Toxicity Profile of Neurotol Plus (Mannitol and Glycerol Combination)
por: Tamta, Anupama, et al.
Publicado: (2009)

The VrrA sRNA controls a stationary phase survival factor Vrp of Vibrio cholerae
por: Sabharwal, Dharmesh, et al.
Publicado: (2015)

LHCb Upgrades and operation at 1034 cm-2 s-1 luminosity –A first study
por: Efthymiopoulos, Ilias, et al.
Publicado: (2018)

1034 Clinical Laboratory Practices in Speciating Organisms and Reporting Results of Voided Urine Cultures
por: Sfeir, Maroun, et al.
Publicado: (2014)

Acute Fascial Space Infections of the Neck: 1034 cases in 17 years follow up
por: Prabhu, Supreet Ratnakar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ujc56cve8eleksj8cte3qankag